Study of plasma transforming growth factor-beta 1 level as a useful tumor marker in various cancers
Immune Network
;
: 143-150, 2001.
Article
in Korean
| WPRIM
| ID: wpr-223972
ABSTRACT
BACKGROUND:
Many investigators have found transforming growth factor-1 (TGF-1) to be elevated in tumors. Changes in responsiveness to TGF-1 have been linked to malignant transformation, tumor progression and tumor regression. Many malignant cell lines of epithelial or hematopoietic origin are refractory to the antiproliferative effects of TGF-1. However, a little is known about the association of TGF-1 with progression of malignant tumor.METHODS:
In this study, we measured the plasma level of TGF-1 in various cancer patients and evaluated the utility of plasma TGF-1 as a possible tumor marker. Plasma TGF-1 levels were measured using enzyme-linked immunosorbent assay in cancer patients and normal controls. Carcinoembryonic antigen (CEA) and alpha-fetoprotein (AFP) as tumor marker were compared with TGF-1 in the aspects of sensitivity and specificity.RESULTS:
The mean of plasma TGF-1 levels was 1.2 19 +/-0.834 ng/ml in normal controls, 5.491 +/-3.598 ng/ml in breast cancer, 12.670 +/-10.386 ng/ml in lung cancer, 5.747 +/-3.228 ng/ml in hepatocellular carcinoma and 10.854 +/-7.996 ng/ml in cervical cancer. In comparison with CEA and AFP, TGF-1 is more sensitive.CONCLUSION:
We conclude that the high levels of TGF-1 are common in the plasma of cancer patients. These result s suggest that the plasma TGF-1 level can be a potent tumor marker in various cancer patients.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Plasma
/
Research Personnel
/
Breast Neoplasms
/
Enzyme-Linked Immunosorbent Assay
/
Alpha-Fetoproteins
/
Carcinoembryonic Antigen
/
Cell Line
/
Uterine Cervical Neoplasms
/
Sensitivity and Specificity
/
Carcinoma, Hepatocellular
Type of study:
Diagnostic study
Limits:
Humans
Language:
Korean
Journal:
Immune Network
Year:
2001
Type:
Article
Similar
MEDLINE
...
LILACS
LIS